Clinical research studyANCA Are Detectable in Nearly All Patients with Active Severe Wegener’s Granulomatosis
Section snippets
Patients and Serum Samples
Samples used in this study were obtained from the Wegener’s Granulomatosis Etanercept Trial (WGET).13 The protocol for WGET was approved by the institutional review board at each participating center. Informed written consent was obtained from all participants. Full details of the study design have been published elsewhere.14 All patients met at least 2 of the 5 modified criteria of the American College of Rheumatology for the classification of Wegener’s granulomatosis14 and had active disease
Results
A description of baseline characteristics of the 180 patients constituting the WGET cohort has been published elsewhere.15 The mean (standard deviation) age was 47 (16) years, there were 108 (60%) men, and the majority (92%) were white. Eighty patients (44%) had newly diagnosed Wegener’s granulomatosis. The median (interquartile range) time since the onset of symptoms was 17 (5-50) months and since diagnosis was 5 (1-36) months. The median (interquartile range) BVAS/WG at entry was 6 (4-9).
At
Discussion
The results of this study indicate that when a multimodality ANCA testing approach is used, nearly all patients with active severe Wegener’s granulomatosis are ANCA positive. In those with active limited disease, ANCA was found in 83%. This study is unique in several respects. First, the WGET cohort is the largest cohort of patients with Wegener’s granulomatosis evaluated in a protocolized fashion. Second, disease activity was recorded with a standardized, validated instrument in all patients.13
Conclusion
Our study demonstrates that almost all patients with active severe Wegener’s granulomatosis have ANCA. A combination of immunofluorescence, direct ELISA, and capture ELISA seems to be required to ensure optimal detection of these antibodies, suggesting that ANCA are a heterogeneous group of antibodies that are not recognized equally well by all testing methods.
References (20)
- et al.
Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features
Kidney Int
(2000) - et al.
Capture-ELISA based on recombinant PR3 is sensitive for PR3-ANCA testing and allows detection of PR3 and PR3-ANCA/PR3 immune complexes
J Immunol Methods
(1998) - et al.
Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions
Clin Immunol
(2002) - et al.
A novel capture-ELISA for detection of anti-neutrophil cytoplasmic antibodies (ANCA) based on c-myc peptide recognition in carboxy-terminally tagged recombinant neutrophil serine proteases
J Immunol Methods
(2005) - et al.
Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo
Blood
(2005) - et al.
Anti-neutrophil cytoplasmic antibodies
Arthritis Rheum
(1998) - et al.
Are there different forms of life in the antineutrophil cytoplasmic antibody universe?
Ann Intern Med
(2005) - et al.
The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis
Ann Intern Med
(1995) - et al.
Anticytoplasmic autoantibodies: their immunodiagnostic value
Ann Intern Med
(1989) - et al.
Diagnostic usefulness of antineutrophil cytoplasmic autoantibody serologyComparative evaluation of commercial indirect fluorescent antibody kits and enzyme immunoassay kits
Am J Clin Pathol
(1999)
Cited by (0)
This study was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH) R01-AR49806 (to U. S.), and funds from the Mayo Foundation. Dr Peikert was supported by NIH training grant T32-HL07897. The WGET trial was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH N01-AR92240 and the Office of Orphan Products, Food and Drug Administration (grant FD-R-001652), General Clinical Research Center Grants M01-RRO-00533 (Boston University), M01-RRO-0042 (The University of Michigan), MO1-RR-30 (Duke University), and M01-RRO-2719 (Johns Hopkins University School of Medicine), from the National Center for Research Resources/NIH. Drs Stone, Merkel, and St Clair were supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases grants K24 AR049185-01, K24 AR2224-01A1, and K24 AR02126-04. Dr Stone is a Hugh and Renna Cosner Scholar in the Center for Innovative Medicine at the Johns Hopkins Bayview Medical Center.
- ⁎
These authors contributed equally and should be considered co-first authors.